These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 6499996)

  • 21. Immunoadjuvant effects of the synthetic muramyl-dipeptide (MDP) N-acetylmuramyl-L-alanyl-D-isoglutamine.
    Heymer B; Finger H; Wirsing CH
    Z Immunitatsforsch Immunobiol; 1978 Oct; 155(1):87-92. PubMed ID: 706536
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Marked enhancement in vivo of adjuvant activity of muramyl dipeptide to protein antigens and to synthetic weak immunogens with monoclonal anti-muramyl dipeptide antibodies.
    Bahr GM; Tello DS; Chedid LA
    Infect Immun; 1985 Aug; 49(2):312-9. PubMed ID: 4018873
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chitosan Nanoparticles Loaded with Whole and Soluble Leishmania Antigens, and Evaluation of Their Immunogenecity in a Mouse Model of Leishmaniasis.
    Hojatizade M; Soleymani M; Tafaghodi M; Badiee A; Chavoshian O; Jaafari MR
    Iran J Immunol; 2018 Dec; 15(4):281-293. PubMed ID: 30593742
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major.
    Gurunathan S; Sacks DL; Brown DR; Reiner SL; Charest H; Glaichenhaus N; Seder RA
    J Exp Med; 1997 Oct; 186(7):1137-47. PubMed ID: 9314562
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cross-protective efficacy from a immunogen firstly identified in Leishmania infantum against tegumentary leishmaniasis.
    Martins VT; Lage DP; Duarte MC; Costa LE; Chávez-Fumagalli MA; Roatt BM; Menezes-Souza D; Tavares CA; Coelho EA
    Parasite Immunol; 2016 Feb; 38(2):108-17. PubMed ID: 26756314
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Administration of monoclonal anti-IFN-gamma antibodies in vivo abrogates natural resistance of C3H/HeN mice to infection with Leishmania major.
    Belosevic M; Finbloom DS; Van Der Meide PH; Slayter MV; Nacy CA
    J Immunol; 1989 Jul; 143(1):266-74. PubMed ID: 2499629
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lipid and lipopolysaccharide-like antigens of Leishmania promastigotes.
    Slutzky GM; Londner MV; Greenblatt CL
    J Protozool; 1985 May; 32(2):347-52. PubMed ID: 4009512
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of immune responses and protection induced by A2 and nucleoside hydrolase (NH) DNA vaccines against Leishmania chagasi and Leishmania amazonensis experimental infections.
    Zanin FH; Coelho EA; Tavares CA; Marques-da-Silva EA; Silva Costa MM; Rezende SA; Gazzinelli RT; Fernandes AP
    Microbes Infect; 2007 Jul; 9(9):1070-7. PubMed ID: 17644455
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Efficacy of the vaccination of C57BL/6 mice against infection with different species of Leishmania].
    Monjour L; Ogunkolade W; Pointet P; Vouldoukis I
    C R Acad Sci III; 1985; 301(18):803-6. PubMed ID: 3936605
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful vaccination against Leishmania chagasi infection in BALB/c mice with freeze-thawed Leishmania antigen and Corynebacterium parvum.
    Vilela Mde C; Gomes DC; Marques-da-Silva Ede A; Serafim TD; Afonso LC; Rezende SA
    Acta Trop; 2007; 104(2-3):133-9. PubMed ID: 17919443
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lower levels of IgG1 in comparison with IgG2a are associated with protective immunity against Leishmania tropica infection in BALB/c mice.
    Rostamian M; Sohrabi S; Kavosifard H; Niknam HM
    J Microbiol Immunol Infect; 2017 Apr; 50(2):160-166. PubMed ID: 26066544
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Leishmania tropica: differences in the antigenicity of promastigotes and amastigotes.
    Sadick MD; Raff HV
    Cell Immunol; 1985 Apr; 91(2):404-14. PubMed ID: 3873282
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prophylactic immunization against experimental leishmaniasis. V. Mechanism of the anti-protective blocking effect induced by subcutaneous immunization against Leishmania major infection.
    Liew FY; Singleton A; Cillari E; Howard JG
    J Immunol; 1985 Sep; 135(3):2102-7. PubMed ID: 3160786
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficient genetically controlled formation of antibody to a synthetic antigen [poly(LTyr, LGlu)-poly(DLAla)- -poly(LLys)] covalently bound to a synthetic adjuvant (N-acetylmuramyl-L-alanyl-D-isoglutamine).
    Mozes E; Sela M; Chedid L
    Proc Natl Acad Sci U S A; 1980 Aug; 77(8):4933-7. PubMed ID: 6776530
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Use of muramyl dipeptides in models of synthetic vaccines].
    Audibert F
    Boll Ist Sieroter Milan; 1985; 64(2):95-102. PubMed ID: 3896261
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PEGylation of cationic liposomes encapsulating soluble Leishmania antigens reduces the adjuvant efficacy of liposomes in murine model.
    Naseri H; Eskandari F; Jaafari MR; Khamesipour A; Abbasi A; Badiee A
    Parasite Immunol; 2017 Nov; 39(11):. PubMed ID: 28921566
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccination of dogs with six different candidate leishmaniasis vaccines composed of a chimerical recombinant protein containing ribosomal and histone protein epitopes in combination with different adjuvants.
    Poot J; Janssen LH; van Kasteren-Westerneng TJ; van der Heijden-Liefkens KH; Schijns VE; Heckeroth A
    Vaccine; 2009 Jul; 27(33):4439-46. PubMed ID: 19500553
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Testing of four Leishmania vaccine candidates in a mouse model of infection with Leishmania (Viannia) braziliensis, the main causative agent of cutaneous leishmaniasis in the New World.
    Salay G; Dorta ML; Santos NM; Mortara RA; Brodskyn C; Oliveira CI; Barbiéri CL; Rodrigues MM
    Clin Vaccine Immunol; 2007 Sep; 14(9):1173-81. PubMed ID: 17626159
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Canine Leishmania vaccines: still a long way to go.
    Gradoni L
    Vet Parasitol; 2015 Feb; 208(1-2):94-100. PubMed ID: 25620293
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Galactose oxidation as a potent vaccine adjuvant strategy. Efficacy in murine models and in protection against a bovine parasitic infection.
    Rhodes J; Zheng B; Morrison CA
    Ann N Y Acad Sci; 1995 May; 754():169-86. PubMed ID: 7625651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.